Drug firm Lupin Ltd. on Monday said its board has approved the transfer of its API R&D division to a wholly owned subsidiary on a slump sale basis.
The company's board has also approved modification to an earlier slump sale transaction by including an additional brand as part of the transfer of OTC business to LUPINLIFE Consumer Healthcare Ltd., on a going concern basis, the drug maker said in a regulatory filing.
ADVERTISEMENT
The company had intimated on Feb. 12 this year regarding the board's approval for the transfer of the OTC Consumer Healthcare Business to a new wholly owned subsidiary.
The company has incorporated LUPINLIFE Consumer Healthcare, a wholly owned subsidiary for the purpose.
Add us to your Preferences
Set as your preferred source on Google
ADVERTISEMENT
RECOMMENDED FOR YOU

PM Narendra Modi To Directly Transfer Rs 7,500 Crore To 75 Lakh Women Across Bihar

SEBI Proposes Easier Tech-Glitch Norms In Brokers' Trading Systems


Lupin Gets USFDA Nod For Generic Risperidone Extended-Release Injectable Suspension


Grounded Jet Airways To Transfer Mumbai Office Space Lease For Rs 370 Crore
